These 10 small-cap U.S. healthcare companies carry the market's most expensive valuations
at seekingalpha.com (Tue, 2-Jun 10:20 AM)
Immix Biopharma’s $150 Million Offering Expands NXC-201 Development—Cash Runway Extends Into 2028
Market Chameleon (Thu, 21-May 7:06 AM)
